Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
ClearOne (Nasdaq: CLRO) entered a definitive merger agreement with Cortigent, a wholly-owned subsidiary of Vivani Medical (Nasdaq: VANI). Cortigent will become a wholly-owned subsidiary of ClearOne at closing.
ClearOne plans a concurrent registered financing targeting a minimum of $10 million and a maximum of $15 million to support the combined company.
Vivani Medical (NASDAQ: VANI) announced the appointment of August J. Moretti to its board of directors and the retirement of Dr. Dean Baker.
Moretti will chair the Audit Committee and join the Compensation Committee, while Baker steps down after leading key board committees and guiding the Nano Precision Medical–Second Sight Medical Products merger.
Vivani Medical (Nasdaq: VANI) received approval from Bellberry, a human research ethics committee in Australia, to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant for obesity and chronic weight management.
The company targets trial initiation in mid-2026, leveraging prior Phase 1 experience with NPM-119, and is preparing a potential dose-ranging efficacy trial, SLIM-2, pending successful SLIM-1 results.
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn, Ph.D., will present a company overview at the 2026 BIO International Convention in San Diego.
The presentation is scheduled for Wednesday, June 24, 2026, at 2:15 p.m. PT in Theater 3 at the San Diego Convention Center, with additional investor and partner meetings planned.
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn will present a company overview at the Jefferies Global Healthcare Conference in New York on June 4, 2026, from 11:05 a.m. to 11:35 a.m. ET. A replay will be available for 90 days on Vivani’s investor website.
Vivani Medical (Nasdaq: VANI) reported Q1 2026 results and a pipeline update. The SLIM-1™ Phase 1 trial of semaglutide implant NPM-139 is expected to start mid-2026, with top-line data by year-end. Vivani held about $28 million in cash and commitments, projected to fund operations through the first half of 2027, and reported a Q1 2026 net loss of $6.8 million. The company is also evaluating paths to separate neuromodulation subsidiary Cortigent into an independent public company.
Vivani Medical (Nasdaq: VANI) reported Q4 and full-year 2025 results and a business update highlighting clinical and preclinical progress for a semaglutide implant (NPM-139) and financing that extends runway into mid-2027.
The company reported sustained preclinical semaglutide exposure with >20% sham-adjusted weight loss for one year, plans to start a Phase 1 study mid-2026 with data possible by end-2026, and raised $41.5M in recent financings.
Vivani (NASDAQ: VANI) announced that subsidiary Cortigent presented 6-year Early Feasibility Study results for the Orion visual cortical prosthesis at NANS 2026. Six subjects implanted 2018–2019 completed the study in March 2025, showing improved visual test performance with devices functional and <4% electrode loss.
One early seizure occurred; stimulation was adjusted and no further serious adverse events were reported. Cortigent plans to discuss a larger pivotal trial with the FDA in 2026.
Vivani Medical (Nasdaq: VANI) closed a registered direct offering and a concurrent private placement on January 27, 2026, selling a combined 3,040,551 shares at $1.48 per share for gross proceeds of approximately $4.5 million before fees and expenses. The private placement included 1,351,351 shares purchased by Chairman Gregg Williams. Proceeds are intended to fund ongoing research and clinical development of NanoPortal implants, plus working capital and general corporate purposes. ThinkEquity acted as sole placement agent for the registered offering.
Vivani Medical (Nasdaq: VANI) priced a best-efforts registered direct offering of 1,689,200 shares and a concurrent private placement of 1,351,351 shares at $1.48 per share.
Gross proceeds are expected to be approximately $4.5 million before fees and expenses. The private placement purchaser is Gregg Williams, chairman of the board. The offerings are expected to close on or about January 27, 2026, and net proceeds will fund research and clinical development, working capital and general corporate purposes.